PD-L1 expression and CD8 positive lymphocytes in human neoplasms
Standard
PD-L1 expression and CD8 positive lymphocytes in human neoplasms : A tissue microarray study on 11,838 tumor samples. / Möller, Katharina; Knöll, Madeleine; Bady, Elena; Schmerder, Max Jonathan; Rico, Sebastian Dwertmann; Kluth, Martina; Hube-Magg, Claudia; Blessin, Niclas C; Mandelkow, Tim; Lennartz, Maximilian; Menz, Anne; Luebke, Andreas M; Höflmayer, Doris; Fraune, Christoph; Bernreuther, Christian; Lebok, Patrick; Uhlig, Ria; Contreras, Hendrina; Weidemann, Sören; Gorbokon, Natalia; Jacobsen, Frank; Clauditz, Till S; Steurer, Stefan; Burandt, Eike; Minner, Sarah; Sauter, Guido; Simon, Ronald; Marx, Andreas H; Krech, Till.
In: CANCER BIOMARK, Vol. 36, No. 2, 2023, p. 177-191.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - PD-L1 expression and CD8 positive lymphocytes in human neoplasms
T2 - A tissue microarray study on 11,838 tumor samples
AU - Möller, Katharina
AU - Knöll, Madeleine
AU - Bady, Elena
AU - Schmerder, Max Jonathan
AU - Rico, Sebastian Dwertmann
AU - Kluth, Martina
AU - Hube-Magg, Claudia
AU - Blessin, Niclas C
AU - Mandelkow, Tim
AU - Lennartz, Maximilian
AU - Menz, Anne
AU - Luebke, Andreas M
AU - Höflmayer, Doris
AU - Fraune, Christoph
AU - Bernreuther, Christian
AU - Lebok, Patrick
AU - Uhlig, Ria
AU - Contreras, Hendrina
AU - Weidemann, Sören
AU - Gorbokon, Natalia
AU - Jacobsen, Frank
AU - Clauditz, Till S
AU - Steurer, Stefan
AU - Burandt, Eike
AU - Minner, Sarah
AU - Sauter, Guido
AU - Simon, Ronald
AU - Marx, Andreas H
AU - Krech, Till
PY - 2023
Y1 - 2023
N2 - BACKGROUND: Programmed death ligand 1 (PD-L1) is the target of immune checkpoint inhibitor therapies in a growing number of tumor types, but a unanimous picture on PD-L1 expression across cancer types is lacking.MATERIALS AND METHODS: We analyzed immunohistochemical PD-L1 expression in 11,838 samples from 118 human tumor types and its relationship with tumor infiltrating CD8 positive lymphocytes.RESULTS: At a cut-off level of 10% positive tumor cells, PD-L1 positivity was seen in 85 of 118 (72%) tumor types, including thymoma (100% positive), Hodgkin's lymphoma (93%), anaplastic thyroid carcinoma (76%), Kaposi sarcoma (71%), sarcomatoid urothelial carcinoma (71%), and squamous cell carcinoma of the penis (67%), cervix (65%), floor of the mouth (61%), the lung (53%), and pharynx (50%). In immune cells, PD-L1 positivity was detectable in 103 (87%) tumor types, including tumors of haematopoetic and lymphoid tissues (75% to 100%), Warthin tumors of the parotid glands (95%) and Merkel cell carcinoma (82%). PD-L1 positivity in tumor cells was significantly correlated with the number of intratumoral CD8 positive lymphocytes across all tumor types as well as in individual tumor types, including serous carcinoma of the ovary, invasive breast carcinoma of no special type, intestinal gastric adenocarcinoma, and liposarcoma (p< 0.0001 each).CONCLUSIONS: PD-L1 expression in tumor and inflammatory cells is found in a wide range of human tumor types. Higher rates of tumor infiltrating CD8 positive lymphocytes in PD-L1 positive than in PD-L1 negative cancers suggest that the antitumor immune response may trigger tumoral PD-L1 expression.
AB - BACKGROUND: Programmed death ligand 1 (PD-L1) is the target of immune checkpoint inhibitor therapies in a growing number of tumor types, but a unanimous picture on PD-L1 expression across cancer types is lacking.MATERIALS AND METHODS: We analyzed immunohistochemical PD-L1 expression in 11,838 samples from 118 human tumor types and its relationship with tumor infiltrating CD8 positive lymphocytes.RESULTS: At a cut-off level of 10% positive tumor cells, PD-L1 positivity was seen in 85 of 118 (72%) tumor types, including thymoma (100% positive), Hodgkin's lymphoma (93%), anaplastic thyroid carcinoma (76%), Kaposi sarcoma (71%), sarcomatoid urothelial carcinoma (71%), and squamous cell carcinoma of the penis (67%), cervix (65%), floor of the mouth (61%), the lung (53%), and pharynx (50%). In immune cells, PD-L1 positivity was detectable in 103 (87%) tumor types, including tumors of haematopoetic and lymphoid tissues (75% to 100%), Warthin tumors of the parotid glands (95%) and Merkel cell carcinoma (82%). PD-L1 positivity in tumor cells was significantly correlated with the number of intratumoral CD8 positive lymphocytes across all tumor types as well as in individual tumor types, including serous carcinoma of the ovary, invasive breast carcinoma of no special type, intestinal gastric adenocarcinoma, and liposarcoma (p< 0.0001 each).CONCLUSIONS: PD-L1 expression in tumor and inflammatory cells is found in a wide range of human tumor types. Higher rates of tumor infiltrating CD8 positive lymphocytes in PD-L1 positive than in PD-L1 negative cancers suggest that the antitumor immune response may trigger tumoral PD-L1 expression.
KW - Female
KW - Humans
KW - Male
KW - B7-H1 Antigen
KW - Carcinoma, Transitional Cell/pathology
KW - CD8-Positive T-Lymphocytes/metabolism
KW - Lymphocytes, Tumor-Infiltrating
KW - Urinary Bladder Neoplasms/pathology
U2 - 10.3233/CBM-220030
DO - 10.3233/CBM-220030
M3 - SCORING: Journal article
C2 - 36683495
VL - 36
SP - 177
EP - 191
JO - CANCER BIOMARK
JF - CANCER BIOMARK
SN - 1574-0153
IS - 2
ER -
